CDMO KBI Biopharma strengthens its positions

| By | CDMO, Contract Manufacturing
0
920

KBI Biopharma, Inc., a biopharmaceutical Contract Development & Manufacturing Organization, has completed the acquisition of the assets of Elion Labs, a leading contract services organization (Colorado, USA) founded to serve the analytical development and product characterization needs of the biopharmaceutical industry.

Elion’s services include analytical method development, qualification and validation, characterization of biologics, and comprehensive data analysis including visualization and interpretation of complex data sets.

This acquisition further strengthens KBI’s analytical and biophysical characterization capabilities following the company’s acquisition of Alliance Protein Laboratories in June 2017. It complements KBI’s neighboring Boulder, CO facility which is focused on development and manufacturing of microbial processes and houses some of KBI’s unique analytical service offerings, such as its Particle Characterization Core Facility. All of Elion’s staff will join KBI, including co-founders John Gabrielson, Brent Kendrick, and Kelly Arthur, who will continue to oversee operations at the Louisville facility.

“Elion has rapidly built a vibrant, growing business and an outstanding reputation for their expertise in characterization of biologics, and we are thrilled to welcome their exceptional team and leadership to KBI,” said KBI President and CEO Tim Kelly. “KBI built our foundation on world-class analytical capabilities which remain at the heart of our business. By incorporating Elion into our company, and combining their unique expertise with Alliance and KBI’s well-established facilities in North Carolina and Colorado, we have established the most powerful analytical capabilities in the biopharmaceutical CDMO industry.”

KBI’s extensive track record of successful programs is a result of its unique approach: applying the insight gained from our advanced biophysical and analytical protein characterization techniques towards the development of robust and scalable processes. KBI delivers accelerated and integrated process development and cGMP manufacturing programs for a wide range of recombinant protein Active Pharmaceutical Ingredients (API) and cell therapies for its clients.

KBI was founded in 1996 and operates US facilities in Durham and Research Triangle Park (North Carolina), Boulder (Colorado), The Woodlands (Texas), and San Diego (California).

SOURCE: kbi biopharma
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.